Endosane is a new take on developing drugs. Endosane is a joint venture of a group of researchers (Prof. Leweke and Dr. Rohleder) and the Sanity Group. Their goal is to apply cannabinoid compounds to develop drugs for neurologic and psychiatric applications.
Our background is in neurology and psychiatry … we think this area has not received as much attention in drug development as it deserves.Max Narr, MD ENDOSANE
A startup’s journey can be a tough one, but it doesn’t have ́to feel like you’re alone on your quest! Invest in others’ success with us by joining our community of entrepreneurs who are building amazing things every day — no matter how big or small their ideas may seem at first glance.
The best way to find investors and cooperation partners for early-stage startups. Sign up here: startupraven.com
In this interview, our guest ist Max Narr (https://www.linkedin.com/in/max-narr-6a3b2a18a), MD at Berlin-based health care startup Endosane (https://endosane.com/). He is also Chief Investment Officer of Sanity Group (https://sanitygroup.com/), which develops products out of the components of cannabis.
Endosane (https://endosane.com/) is a joint venture of Sanity Group (https://sanitygroup.com/) and a group of researchers. Max says it is Sanity’s take on developing drugs, partly based on cannabis derivatives. Their drug development is advancing the research of Prof. Leweke and Dr. Rohleder on cannabinoids for medical use.
Endosane has close ties (capital and personal wise) with Sanity Group. You can learn more about Finn Hänsel, the founder of Sanity Group, and his plans for the future in our interview with him here: https://open.spotify.com/episode/1TXps03Uxzb8hv0KvOVIpN?si=b17a5f2f3cbe40a4
Find all links and show notes on our blog: https://medium.com/@startuprad_io/endosane-brings-new-hope-for-patients-with-mental-health-conditions-7513dcfefa7b